[Management of Acute Coronary Syndrome]

Overview

Journal Herz

Date 2025 Jan 10

PMID 39792316

Authors

Maria Buske

Hans-Josef Feistritzer

Alexander Jobs

Holger Thiele

Affiliations

Soon will be listed here.

Abstract

Coronary artery disease (CAD) is the leading cause of death worldwide. Acute coronary syndrome (ACS) encompasses a spectrum of diagnoses ranging from unstable angina pectoris to myocardial infarction with and without ST-segment elevation and frequently presents as the first clinical manifestation. It is crucial in this scenario to perform a timely and comprehensive assessment of patients by evaluating the clinical presentation, electrocardiogram and laboratory diagnostics using highly sensitivity cardiac troponin in order to initiate a timely and risk-adapted continuing treatment with immediate or early invasive coronary angiography. In addition to revascularization, the subsequent antithrombotic and lipid-lowering treatment plays a major role in the further secondary prevention of CAD. The choice and duration of medication over time should be tailored to the individual risk profile of the patient. Furthermore, appropriate patient education regarding risk factor management is of paramount importance.

References

Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D . European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022; 43(8):716-799. DOI: 10.1093/eurheartj/ehab892. View

Thygesen K, Alpert J, Jaffe A, Chaitman B, Bax J, Morrow D . Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018; 138(20):e618-e651. DOI: 10.1161/CIR.0000000000000617. View

Byrne R, Rossello X, Coughlan J, Barbato E, Berry C, Chieffo A . 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44(38):3720-3826. DOI: 10.1093/eurheartj/ehad191. View

Valgimigli M, Gagnor A, Calabro P, Frigoli E, Leonardi S, Zaro T . Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015; 385(9986):2465-76. DOI: 10.1016/S0140-6736(15)60292-6. View

Jolly S, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P . Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011; 377(9775):1409-20. DOI: 10.1016/S0140-6736(11)60404-2. View

Silvain J, Beygui F, Barthelemy O, Pollack Jr C, Cohen M, Zeymer U . Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012; 344:e553. PMC: 3271999. DOI: 10.1136/bmj.e553. View

Yusuf S, Mehta S, Chrolavicius S, Afzal R, Pogue J, Granger C . Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006; 354(14):1464-76. DOI: 10.1056/NEJMoa055443. View

Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R . PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med. 2017; 377(25):2419-2432. DOI: 10.1056/NEJMoa1710261. View

Mehta S, Wood D, Storey R, Mehran R, Bainey K, Nguyen H . Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2019; 381(15):1411-1421. DOI: 10.1056/NEJMoa1907775. View

10.

Bianchini E, Basile M, Bianchini F, Zito A, Romagnoli E, Aurigemma C . Multivessel revascularization in non-ST segment elevation acute coronary syndromes: A systematic review and meta-analysis of 182,798 patients. Int J Cardiol. 2024; 413:132392. DOI: 10.1016/j.ijcard.2024.132392. View

11.

Ndrepepa G, Berger P, Mehilli J, Seyfarth M, Neumann F, Schomig A . Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008; 51(7):690-7. DOI: 10.1016/j.jacc.2007.10.040. View

12.

Wiviott S, Braunwald E, McCabe C, Montalescot G, Ruzyllo W, Gottlieb S . Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20):2001-15. DOI: 10.1056/NEJMoa0706482. View

13.

Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045-57. DOI: 10.1056/NEJMoa0904327. View

14.

Schupke S, Neumann F, Menichelli M, Mayer K, Bernlochner I, Wohrle J . Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019; 381(16):1524-1534. DOI: 10.1056/NEJMoa1908973. View

15.

James S, Roe M, Cannon C, Cornel J, Horrow J, Husted S . Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011; 342:d3527. PMC: 3117310. DOI: 10.1136/bmj.d3527. View

16.

Palmerini T, Della Riva D, Benedetto U, Reggiani L, Feres F, Abizaid A . Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J. 2017; 38(14):1034-1043. PMC: 5837418. DOI: 10.1093/eurheartj/ehw627. View

17.

Hahn J, Song Y, Oh J, Cho D, Lee J, Doh J . 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018; 391(10127):1274-1284. DOI: 10.1016/S0140-6736(18)30493-8. View

18.

Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V . Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ. 2018; 363:k3793. PMC: 6167608. DOI: 10.1136/bmj.k3793. View

19.

De Luca G, Damen S, Camaro C, Benit E, Verdoia M, Rasoul S . Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention. 2019; 15(11):e990-e998. DOI: 10.4244/EIJ-D-19-00539. View

20.

Giustino G, Mehran R, Dangas G, Kirtane A, Redfors B, Genereux P . Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. J Am Coll Cardiol. 2017; 70(15):1846-1857. DOI: 10.1016/j.jacc.2017.08.018. View